High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kim, Ekaterina [1 ]
Sivina, Mariela [1 ]
Vaca, Alicia [1 ]
Ferrajoli, Alessandra [1 ]
Jain, Nitin [2 ]
Thompson, Philip A. [1 ]
Wierda, William G. [1 ]
Wodarz, Dominik [3 ]
Chiorazzi, Nicholas [4 ]
Burger, Jan A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Feinstein Inst Med Res, Karches Ctr Oncol Res, Manhasset, NY USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4140 / 4141
页数：2
相关论文
共 50 条
  • [31] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [32] Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL).
    Jones, Jade
    George, Binsah
    Peterson, Christine B.
    Burger, Jan Andreas
    Jain, Nitin
    Wierda, William G.
    Keating, Michael J.
    Durand, Jean-Bernard
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Davids, Matthew S.
    Chang, Julie
    Ma, Shuo
    Biondo, Juliana
    Mobasher, Mehrdad
    Mun, Yong
    Mato, Anthony R.
    BLOOD, 2018, 132
  • [34] Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy
    Loury, David
    Sukbuntherng, Juthamas
    Clow, Fong
    James, Danelle Frances
    Kunkel, Lori A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Kenderian, Saad S.
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Leis, Jose
    Chanan-Khan, Asher
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1376 - 1383
  • [36] Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)
    Khelifi, Rania S.
    Huang, Steven J. T.
    Savage, Kerry J.
    Villa, Diego
    Scott, David W.
    Ramadan, Khaled
    Connors, Joseph M.
    Sehn, Laurie H.
    Toze, Cynthia L.
    Gerrie, Alina S.
    BLOOD, 2020, 136
  • [37] Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib plus R) in Patients with Chronic Lymphocytic Leukemia (CLL)
    Burger, Jan A.
    Sivina, Mariela
    Ferrajoli, Alessandra
    Jain, Nitin
    Kim, Ekaterina
    Kadia, Tapan
    Estrov, Zeev
    Gonzalez, Graciela Nogueras
    Huang, Xuelin
    Ohanian, Maro
    Andreeff, Michael
    Thomas, Mathew
    Alexander-Williams, Lynette
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Wierda, William G.
    Keating, Michael J.
    BLOOD, 2017, 130
  • [38] Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study
    Rogers, Kerry A.
    Flinn, Ian W.
    Stephens, Deborah M.
    Kipps, Thomas J.
    Larson, Sarah
    McGarry, Carolyn
    Hassounah, Nadia B.
    Gou, Liangke Connie
    Woo, Janghee
    Byrd, John C.
    BLOOD, 2021, 138
  • [39] The causes of death and the impact of age on the survival of patients with chronic lymphocytic leukemia (CLL).
    Flynn, JM
    Byrd, JC
    Diehl, LF
    BLOOD, 1999, 94 (10) : 298B - 298B
  • [40] The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study
    Gordon, Max J.
    Kaempf, Andy
    Sitlinger, Andrea
    Salous, Tareq
    Alqahtani, Hamood
    Churnetski, Michael C.
    Wisniewski, Paul
    Rivera, Xavier Issac
    Patel, Krish
    Persky, Daniel O.
    Cohen, Jonathon B.
    Choi, Michael Y.
    Hill, Brian T.
    Shadman, Mazyar
    Stephens, Deborah M.
    Brander, Danielle M.
    Park, Byung
    Danilov, Alexey
    BLOOD, 2020, 136
12345